Sanofi Discontinues Japan Phase II Trials, Global Development With JAK2 Inhibitor For Bone Marrow Fibrosis
This article was originally published in PharmAsia News
Executive Summary
Sanofi will stop the development of the JAK2 inhibitor fedratinib, a drug planned for the treatment of myelofibrosis, the company announced on Nov. 21.